Data from the ORBITA-2 randomized, placebo-controlled trial emphasize that patient age alone should not be the deciding ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. PCI improved angina symptoms at 12 weeks vs. a sham ...
A recent state-of-the-art review overlooks a “safe and effective” therapy for patients with stable angina and no good treatment options, according to several cardiologists. The coronary sinus reducer ...
PARIS — After the first major prospective study to associate percutaneous intervention (PCI) with symptom relief in stable angina captured international attention, a new analysis of the ...
A new study conducted by researchers at the Imperial College London suggests that the placebo effect experienced by patients who receive coronary artery stents might be larger than expected, even ...
Please provide your email address to receive an email when new articles are posted on . Abnormal FFR-CT findings were significantly prognostic of poor long-term outcomes in patients with stable angina ...
Complete revascularization with PCI results in better health status for patients with multivessel, stable CAD than either incomplete revascularization or a conservative strategy of guideline-directed ...
Researchers at the University of Illinois Chicago have received a $3.12 million National Institutes of Health grant to study whether acupuncture can alleviate chest pain caused by stable angina.
– The IMPROVE-ISCHEMIA Phase 2 clinical trial met the primary endpoint of tolerability and safety; 8-weeks treatment with ninerafaxstat also demonstrated a statistically significant improvement in ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window PHILADELPHIA -- ...
Angina pectoris, often shortened to angina, is chest pain or discomfort caused by reduced blood flow to the heart and most commonly - but not always - a symptom of coronary artery disease (CAD). The ...
Midphase data are arriving thick and fast at Imbria Pharmaceuticals. Days after sharing positive top-line data in one indication, the cardiometabolic biotech has reported a phase 2 trial of the same ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results